Posts From the monthly archives: "November 2012"

UK lagging behind with bowel cancer drug test A study funded by Merck Serono (distributors of cetuximab outside of North America; CDx biomarkers for cetuximab = EGFR+ and KRAS-) found that only 44% of all bowel cancer patients in the UK received testing for KRAS mutations (test price = £120, refunded by Merck Serono). There…(Read More)

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access